These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24511859)

  • 21. Optimizing the diagnosis of early Alzheimer's disease in mild cognitive impairment subjects.
    Mattila J; Soininen H; Koikkalainen J; Rueckert D; Wolz R; Waldemar G; Lötjönen J
    J Alzheimers Dis; 2012; 32(4):969-79. PubMed ID: 22890102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria.
    Carrillo MC; Dean RA; Nicolas F; Miller DS; Berman R; Khachaturian Z; Bain LJ; Schindler R; Knopman D;
    Alzheimers Dement; 2013 Sep; 9(5):594-601. PubMed ID: 24007744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease.
    Silveira de Souza A; de Oliveira-Souza R; Moll J; Tovar-Moll F; Andreiuolo PA; Bottino CM
    Dement Geriatr Cogn Disord; 2011; 32(5):351-61. PubMed ID: 22311276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mild cognitive impairment due to alzheimer disease is less likely under the age of 65.
    Shin S; Kim JH; Cho JH; Kim GS; Choi SA; Lee JH;
    Alzheimer Dis Assoc Disord; 2015; 29(1):26-31. PubMed ID: 24759547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is it Alzheimer's disease?
    Gambert SR
    Postgrad Med; 1997 Jun; 101(6):42-3, 48-9, 52-4 passim. PubMed ID: 9194865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New diagnostic criteria for Alzheimer's disease.
    Zetterberg H
    Biomark Med; 2011 Aug; 5(4):407-9. PubMed ID: 21861660
    [No Abstract]   [Full Text] [Related]  

  • 28. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addressing Alzheimer's: a pragmatic approach.
    Menchola M; Weiss BD
    J Fam Pract; 2015 Jan; 64(1):10-8. PubMed ID: 25574508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Tower of London Test: different scoring criteria for diagnosing Alzheimer's disease and mild cognitive impairment.
    de Paula JJ; Moreira L; Nicolato R; de Marco LA; Côrrea H; Romano-Silva MA; de Moraes EN; Bicalho MA; Malloy-Diniz LF
    Psychol Rep; 2012 Apr; 110(2):477-88. PubMed ID: 22662402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
    Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
    Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?
    Davey DA
    Womens Health (Lond); 2013 May; 9(3):279-90. PubMed ID: 23638783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment.
    Buschert VC; Giegling I; Teipel SJ; Jolk S; Hampel H; Rujescu D; Buerger K
    J Clin Psychiatry; 2012 Dec; 73(12):e1492-8. PubMed ID: 23290333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffusion tensor imaging measures of normal appearing white matter in patients who are aging, or have amnestic mild cognitive impairment, or Alzheimer's disease.
    Wang JH; Lv PY; Wang HB; Li ZL; Li N; Sun ZY; Zhao BH; Huang Y
    J Clin Neurosci; 2013 Aug; 20(8):1089-94. PubMed ID: 23787190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baroreflex function is reduced in Alzheimer's disease: a candidate biomarker?
    Meel-van den Abeelen AS; Lagro J; Gommer ED; Reulen JP; Claassen JA
    Neurobiol Aging; 2013 Apr; 34(4):1170-6. PubMed ID: 23140588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.